Adva-27a is Sunshine Biopharma’s lead anti-cancer compound that kills Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The pre-IND-Enabling studies include in vitro biological tests and studies in live rats and mice to ensure that the scale-up manufacturing process produces a compound that is similar to the one used in the pre-clinical studies.
Sunshine Biopharma CFO Camille Sebaaly said the company is excited to be at the scale-up stage and have the capacity to manufacture gram quantities of Adva-27a compound.
"This is a very important milestone in our Adva-27a development program," Sebaaly added.